ESMO 2019 | Updates on JAVELIN renal 101: primary treatment for patients

Laurence Albiges

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses the updated results seen in the JAVELIN renal 101 study (NCT02684006), regarding the combination therapy of avelumab plus axitinib versus sunitinib as a first-line treatment of advanced renal cell carcinoma. Dr Albiges focuses primarily on the group of participants for whom this is primary treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video